4doh: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4doh]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4DOH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4DOH FirstGlance]. <br> | <table><tr><td colspan='2'>[[4doh]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4DOH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4DOH FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.8Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4doh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4doh OCA], [https://pdbe.org/4doh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4doh RCSB], [https://www.ebi.ac.uk/pdbsum/4doh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4doh ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4doh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4doh OCA], [https://pdbe.org/4doh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4doh RCSB], [https://www.ebi.ac.uk/pdbsum/4doh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4doh ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[https://www.uniprot.org/uniprot/IL20_HUMAN IL20_HUMAN] Cytokine that may be involved in epidermal function and psoriasis. Acts through STAT3. | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Latest revision as of 05:47, 21 November 2024
IL20/IL201/IL20R2 Ternary ComplexIL20/IL201/IL20R2 Ternary Complex
Structural highlights
FunctionIL20_HUMAN Cytokine that may be involved in epidermal function and psoriasis. Acts through STAT3. Publication Abstract from PubMedInterleukin 20 (IL-20) is a pleotropic IL-10 family cytokine that protects epithelial surfaces from pathogens. However, dysregulated IL-20 signaling is implicated in several human pathologies including psoriasis, rheumatoid arthritis, atherosclerosis, and osteoporosis. IL-20, and related cytokines IL-19 and IL-24, designated IL-20 subfamily cytokines (IL-20SFCs), induce cellular responses through an IL-20R1/IL-20R2 (type I) receptor heterodimer, whereas IL-20 and IL-24 also signal through the IL-22R1/IL-20R2 (type II) receptor complex. The crystal structure of the IL-20/IL-20R1/IL-20R2 complex reveals how type I and II complexes discriminate cognate from noncognate ligands. The structure also defines how the receptor-cytokine interfaces are affinity tuned to allow distinct signaling through a receptor complex shared by three different ligands. Our results provide unique insights into the complexity of IL-20SFC signaling that may be critical in the design of mechanistic-based inhibitors of IL-20SFC-mediated inflammatory disease. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines.,Logsdon NJ, Deshpande A, Harris BD, Rajashankar KR, Walter MR Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12704-9. Epub 2012 Jul 16. PMID:22802649[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||